Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 16/20 | 1.00 |
| ▸ | AGXT | P21549 | 10/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5526648 | 0.98 | IDO1 (1.00) | IDO1AGXTCYP3A4 | |
| SCHEMBL11341386 | 0.81 | IDO1 (0.68) | IDO1 | |
| SCHEMBL2293769 | 0.81 | IDO1 (0.68) | IDO1 | |
| SCHEMBL438248 | 0.80 | IDO1 (0.78) | IDO1AGXTCYP3A4 | |
| SCHEMBL764954 | 0.79 | IDO1 (0.65) | IDO1 | |
| SCHEMBL19215657 | 0.77 | IDO1 (0.63) | IDO1 | |
| SCHEMBL17037240 | 0.77 | IDO1 (0.63) | IDO1 | |
| SCHEMBL2096474 | 0.77 | IDO1 (0.63) | IDO1 | |
| SCHEMBL260335 | 0.77 | IDO1 (0.63) | IDO1 | |
| SCHEMBL19121843 | 0.77 | IDO1 (0.63) | IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070244117-A1 | Novel Hydroxamic Acid Esters and Pharmaceutical Use Thereof | LEO PHARMA A/S (DK) | 2007-10-18 | — | — | US | claimed |
| CN-1906155-A | Novel hydroxamic acid esters and pharmaceutical use thereof | LEO PHARMA AS (DK) | 2007-01-31 | — | — | CN | claimed |
| US-9353144-B2 | Vascular leakage inhibitor | INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY (KR) | 2016-05-31 | — | — | US | disclosed |
| US-20150238948-A1 | POLYMERIC AND SOLID-SUPPORTED CATALYSTS, AND METHODS OF DIGESTING LIGNIN-CONTAINING MATERIALS USING SUCH CATALYSTS | Midori Renewables, Inc. (US) | 2015-08-27 | — | — | US | disclosed |
| US-20140378399-A1 | NOVEL VASCULAR LEAKAGEAGE INHIBITOR | CURACLE CO., LTD. (KR) | 2014-12-25 | — | — | US | disclosed |
| US-8034811-B2 | Hydroxamic acid esters and pharmaceutical use thereof | LEO PHARMA A/S (DK) | 2011-10-11 | — | — | US | disclosed |
| EP-1697312-B1 | HYDROXAMIC ACID ESTERS AND PHARMACEUTICAL USE THEREOF | LEO PHARMA AS (DK) | 2011-07-20 | — | — | EP | disclosed |
| US-20070244117-A1 | Novel Hydroxamic Acid Esters and Pharmaceutical Use Thereof | LEO PHARMA A/S (DK) | 2007-10-18 | — | — | US | disclosed |
| CN-1906155-A | Novel hydroxamic acid esters and pharmaceutical use thereof | LEO PHARMA AS (DK) | 2007-01-31 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140378399-A1 | NOVEL VASCULAR LEAKAGEAGE INHIBITOR | PGF, VEGFA, VCAM1 | IDO1 4844/4885AGXT 3473/4885CYP3A4 3782/4885 |
| US-20070244117-A1 | Novel Hydroxamic Acid Esters and Pharmaceutical Use Thereof | F9, F12, HDAC9 | IDO1 3029/4885AGXT 131/4885CYP3A4 3344/4885 |
| US-20150238948-A1 | POLYMERIC AND SOLID-SUPPORTED CATALYSTS, AND METHODS OF DIGESTING LIGNIN-CONTAINING MATERIALS USING SUCH CATALYSTS | LCT, AGL, MGAM | IDO1 2174/4885AGXT 296/4885CYP3A4 1768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.